NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diatrizoate meglumine is a high-osmolality contrast medium administered by injection for radiographic imaging procedures. It enhances visualization of blood vessels, organs, and body cavities during diagnostic imaging studies. The agent works by absorbing X-rays more readily than surrounding tissue, creating radiographic contrast.
LOE Approaching
As a legacy contrast agent approaching loss of exclusivity, the brand team is likely small and focused on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on diatrizoate meglumine offers limited career growth opportunity given its mature lifecycle and approaching loss of exclusivity. Positions tied to this product are typically focused on cost management, market defense, and transition planning rather than innovation or expansion.
Brand Manager (legacy/transition)Sales Representative
Worked on DIATRIZOATE MEGLUMINE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.